NIH allies with 11 top cancer biopharma players in $215M drive to explore biomarkers, speed R&D
A who’s who of cancer drug R&D companies have banded together to help fund a $215 million drive at the NIH to explore relevant biomarkers that can help focus immunotherapies on the right patient population while cutting the amount of time it takes to drive better studies through the clinic.
The NIH plans to put up the bulk of the money itself, up to $160 million — depending on its budget — while each of the biopharma companies involved put up $1 million each for 5 years for another $55 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
